BETRF (BetterLife Pharma) Other Long Term Assets: $0.00 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BETRF BetterLife Pharma Inc BETRF
16 GF Score
Price $0.22
! 1 Warning Sign
View Full Analysis

What is BetterLife Pharma Other Long Term Assets?

BetterLife Pharma BETRF -18.04% 16 Other Long Term Assets is $0.00 Mil as of Apr. 2026. GuruFocus rates BETRF with a GF Score™ of 16/100. The stock has 1 warning sign investors should review.

BetterLife Pharma's other long-term assets for the quarter that ended in Apr. 2026 was $0.00 Mil.

BetterLife Pharma Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for BetterLife Pharma's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BetterLife Pharma Other Long Term Assets Chart

BetterLife Pharma Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BetterLife Pharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BETRF
16GF Score
BetterLife Pharma Inc BETRF
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BetterLife Pharma Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of $0.00 Mil mean?
BetterLife Pharma (BETRF) has a Other Long Term Assets of $0.00 Mil as of Apr. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on BetterLife Pharma and its competitors.
Is BetterLife Pharma's Other Long Term Assets too high?
BetterLife Pharma's current Other Long Term Assets is $0.00 Mil. Overall, BetterLife Pharma has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does BetterLife Pharma's Other Long Term Assets compare to VRTX and REGN?
BetterLife Pharma's Other Long Term Assets of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Biotechnology company?
A good Other Long Term Assets depends on the Biotechnology industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on BetterLife Pharma and its competitors. BetterLife Pharma's current Other Long Term Assets is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BetterLife Pharma stock overvalued right now?
BetterLife Pharma (BETRF) has a current Other Long Term Assets of $0.00 Mil. The current Other Long Term Assets is $0.00 Mil. BetterLife Pharma's overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For BetterLife Pharma (BETRF), the current Other Long Term Assets is $0.00 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BetterLife Pharma Business Description

Other Exchanges NPAU:GermanyBETR:Canada
Address 1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6
BetterLife Pharma Inc is a biopharmaceutical company engaged in the development of patented pharmaceuticals. It is an emerging biotechnology company mainly focused on developing compounds for the treatment of mental disorders. It is also refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight viral infections. The Company operates in one industry segment, development and commercialization of patented pharmaceuticals within one geographical area.
16GF Score

Get the complete analysis for BETRF

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.22
Price